Epi-Max®, cleared by the FDA for sale in the U.S. in 2005, has created “very encouraging initial feedback” from clinical evaluations underway, according to Greg Pilant, CEO of Dermagenics, U.S., Inc., a wholly owned subsidiary of Greystone Pharmaceuticals, Inc. and the producer of Epi-Max. Epi-Max, an aceytelated regenerated cellulose (ARC) sterile wound dressing, is a prescription combination device that provides the benefits of an innovative wound dressing with dual active ingredients. It is indicated for use to manage pressure ulcers (stages I-IV), stasis ulcers, diabetic skin ulcers, skin irritations, cuts, and abrasions. (PRWEB May 18, 2006) Trackback URI: http://www.prweb.com/zingpr.php/RW1wdC1Db3VwLUluc2UtQ3Jhcy1IYWxmLVplcm8=


Click Here to read the entire article...